Special Issue

Advanced Research in Endometriosis

Message from the Guest Editor

Endometriosis is a chronic inflammatory benign disease commonly found in women of reproductive age. However, it can affect people of all ages and has been found in men, animals, as well as fetuses. Unfortunately, 7-10 years pass until the diagnosis is made. This Special Issue provides is an excellent opportunity for a thorough analysis of the pathophysiology of the disease, the signs and symptoms, and the type of pain. Categories of endometriosis can be identified and conservative and surgical techniques can be provided. An important research area is the pain correlated with endometriosis. One of the causative factors of pain in endometriosis is inflammation. The suppression of inflammatory mediators by inhibiting their synthesis might offer novel and effective treatments for the inflammatory pain in endometriosis. This Special Issue welcomes new and innovative original studies and detailed reviews in this field.

Guest Editor

Dr. Nikolaos Machairiotis

Department Obstetrics/Gynaecology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Watford Rd, Harrow HA1 3UJ, London, UK

Deadline for manuscript submissions

closed (31 December 2020)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/42891

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/ biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health. Boston. MA 02115. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).